IFITM1 and triple-negative breast carcinoma: It has been shown that IFITM1 is tightly regulated by the proliferation, migration, and invasion of breast cancer and inhibits apoptosis, and that inhibition of IFITM1 expression by disrupting interferon-α and NF-κB crosstalk can attenuate triple-negative breast cancer progression [19, 20], which may be one of the novel immunomarkers for endometrial cancer stromal cells [20], and knockdown of IFITM1 in pancreatic cancer was also found to inhibit the proliferation of cells, that induced cell cycle arrest and apoptosis, and inhibited cancer progression [21].